OmniAb signs global ion channel collaboration with Eli Lilly

HUTCHMED reports positive Phase III results for ORPATHYS and TAGRISSO combination

Phanes Therapeutics' Spevatamig receives US FDA Fast Track designation in advanced and metastatic biliary tract carcinoma

ArkBio's Ziresovir gains US FDA Phase II clinical trial approval

Elephas Biosciences partners Neuberg Diagnostics

Pilot Project between BioCytics and LIDE Biotech

Pharming launches Joenja in Japan for APDS patients aged four and above

PTC to acquire BLA-stage ST-920 Fabry disease programme

ArkBio's IND application for AFC candidate AK0406 approved in China for influenza prophylaxis

Definium Therapeutics reports positive Phase 3 results for DT120 in generalised anxiety disorder

Astorg completes acquisition of Thermo Fisher Scientific's microbiology business

Natera to support Phase 1 trial of Kupando's immunotherapy in advanced skin cancers

Graviton BioScience's Investigational New Drug (IND) application for GV101 cleared for Friedreich's ataxia treatment

Laekna's New Drug Application for LAE002 (afuresertib) accepted by China's NMPA

EIT Pharma's lonafarnib New Drug Application accepted for review by US FDA for chronic hepatitis D treatment